Clinical value of MRI, serum SCCA, and CA125 levels in the diagnosis of lymph node metastasis and para-uterine infiltration in cervical cancer

Abstract

Background Cervical cancer shows great differences in depth of invasion, metastasis, and other biological behaviors. The location of the lesion is special, so it is usually difficult to determine the clinical stage. This study aimed to explore the clinical value of magnetic resonance imaging (MRI) and tumor serum markers for the preoperative diagnosis of cervical cancer lymph node metastasis and para-uterine invasion. Methods A total of 200 patients with cervical cancer admitted to our hospital from January 2019 to January 2020 were collected as the research subjects. Comparing the diagnosis results of preoperative MRI scan, serum tumor markers, and postoperative pathological examination using single factor comparison, we determined the MRI scan results, the comprehensive matching rate between serum tumor markers (squamous cell carcinoma antigen (SCCA), carbohydrate antigen 125 (CA125)) and postoperative pathological results, and the differences of sensitivity, specificity, and accuracy in the prediction of lymph node metastasis and para-uterine infiltration of cervical cancer. Results The levels of SCCA and CA125 in patients with para-uterine invasion and lymph node metastasis were higher than those of patients without invasion and metastasis. Among them, the level of SCCA was significantly different (P<0.05). The level of CA125 was not statistically significant (P>0.05), so MRI combined with serum SCCA was selected for combined diagnosis in the later period. The sensitivity, specificity, and accuracy of MRI diagnosis of cervical cancer and para-uterine infiltrating lymph node metastasis and metastasis were 55.2, 91.6, and 89.5% and 55.2, 91.6, and 89.5%, respectively. These data in MRI combined with serum SCCA were 76.3, 95.3, and 94.3% and 63.2, 96.0, and 95.1%, respectively. The accuracy of tumor markers combined with MRI in the diagnosis of cervical cancer lymph node metastasis and para-uterine invasion was higher than that of MRI. Conclusions MRI combined with serum SCCA can more accurately identify cervical cancer lymph node metastasis and para-uterine invasion compared with MRI alone. Tumor marker combined with MRI diagnosis is an important auxiliary method for cervical cancer treatment and can provide comprehensive and reliable clinical evidence for evaluation before cervical cancer surgery.

Magnetic Fields and Cancer: Epidemiology, Cellular Biology, and Theranostics

“…MRI, CT/MRI, and PET/MRI have been used for cervical cancer staging and lymph node metastasis [474,475], and PET/MRI was found to possess a higher diagnostic sensitivity [476], specificity [477], and accuracy [478,479], also during pregnancy [480], being helpful in clinical diagnosis [481], prediction [482], and treatment [483,484]. MRI diagnosis is an auxiliary method for cervical cancer treatment when used in combination with tumor markers (e.g., squamous cell carcinoma antigen) [485] and for the management of women with early cervical cancer [486]. DWI-MRI and ADC are used as a non-invasive imaging methods for characterizing the fraction of collagen I-positive tissue across different tumor models of uterine cervical cancer [487], for the pathological grade of tumor [488], for the differentiation between metastatic and non-metastatic pelvic lymph nodes [489], and between normal and cancerous tissue in the uterine cervix [490].…”

Construction of Nursing Practice Model in Case Management of Concurrent Chemotherapy and Radiochemotherapy Treatment in Cervical Cancer

“…Around 500 thousand people worldwide are diagnosed with cervical cancer every year, and about 260 thousand people die. The incidence rate is gradually younger, and its annual incidence rate is increasing by about 5% [1]. It has been the world's second [2] in recent years.…”

Prognostic significance of serum CA125 in the overall management for patients with gastrointestinal stromal tumors

“…Serum tumor marker CA125 has been one of the common laboratory tests for most patients with malignant tumors before operation as its concentration is elevated in numerous tumors [ 14 , 15 ]. Many clinical studies of gynecologic malignancies incorporated CA125 as a serum marker that indicates tumorigenesis and metastasis [ 16 , 17 ]. As an easily accessible clinical examination, CA125 also played a key role in the diagnosis of gastrointestinal malignant tumors [ 18 , 19 ].…”